Neogenomics Inc.
NEO
Market Cap$1.76B
Close$
$-12.82
191.3% downside
Current Fair Value
191.3% downsideOvervalued by 191.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.76 Billion |
|---|---|
| Enterprise Value | $1.88 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.7 |
| Beta | 1.65 |
| Outstanding Shares | 127,665,638 |
| Avg 30 Day Volume | 656,717 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -19.98 |
|---|---|
| PEG | 54.23 |
| Price to Sales | 3.51 |
| Price to Book Ratio | 2.0 |
| Enterprise Value to Revenue | 3.18 |
| Enterprise Value to EBIT | -19.46 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
ESG Score
No data
About Neogenomics Inc.
1,600 employeesNeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...